Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
62cu-ethylglyoxal bis(thiosemicarbazone)
- Development stage
- Phase 2
- Lead developer
- Proportional Technologies
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
62Cu-ethylglyoxal bis(thiosemicarbazone) (62Cu-ETS) is a lipophilic radiopharmaceutical used as a positron emission tomography (PET) imaging tracer for the quantification of regional blood flow, particularly in the kidneys. Developed by Jeffrey L. Lacy and colleagues, it utilizes the short-lived positron emitter copper-62 (half-life of 9.74 minutes), which can be produced on-site using a zinc-62/copper-62 generator. The tracer's mechanism involves rapid extraction from the blood and intracellular trapping, making it an effective agent for measuring renal blood flow (RBF) as an alternative to 15O-water. It has been evaluated in Phase 2 clinical trials for assessing renal perfusion in healthy volunteers and patients with renal disease or arterial blockages.
- Other names
- Copper-62 ethylglyoxal bis(thiosemicarbazone)
02
Targets
Biological membrane
Beyond the preview
Go deeper on 62cu-ethylglyoxal bis(thiosemicarbazone).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 62cu-ethylglyoxal bis(thiosemicarbazone).